Prestige Biologics Adjusts Convertible Bond Conversion Price Down to 2,474 Won, Raising Dilution Concerns for Shareholders
Prestige Biologics announced on June 22, 2026 a downward adjustment of the conversion price for its 3rd series unsecured private convertible bond from 2,747 won to 2,474 won due to market price decline.
This adjustment sets the minimum conversion price at 2,474 won, 70% of the initial price of 3,534 won. The convertible bonds can be converted into 12,874,929 shares, representing a potential dilution of 16.56% of current outstanding shares, a significant dilution risk.
The proceeds of 45.5 billion won are intended for operating expenses including manufacturing site certification and purchase of raw materials for large orders. The bonds mature on March 20, 2027, with 0% coupon and 4.83% yield to maturity.
The bondholder is Octava Fund Limited, an offshore fund with low financial transparency and poor recent financial performance, posing governance risks.
[AI Summary]Prestige Biologics' downward conversion price adjustment exacerbates shareholder dilution risk. While the use of funds for operations supports growth, the large potential dilution and low governance transparency weigh negatively on shareholder value.
KOSDAQ Filing Information
[Correction of Description] Report on Major Matters (Decision on Issuance of Convertible Bonds)